(Reuters) - Geoff Meacham, an analyst at JP Morgan, said MedImmune has historically had a number of problems with Synagis in connection with reimbursement and prior authorization.
"As such, we suspect the first-quarter strength has more to do with inventory stocking rather than resolution of these intermediate to longer term issues," he said in a research report.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment